Article
Medicine, General & Internal
C. Mettler, C. A. Durel, P. Guilpain, B. Bonnotte, F. Cohen-Aubart, M. Hamidou, J. C. Lega, V Le Guern, F. Lifermann, V Poindron, G. Pugnet, A. Servettaz, X. Puechal, L. Guillevin, B. Terrier
Summary: This retrospective study examines the efficacy and safety of off-label use of biologics for refractory and/or relapsing granulomatosis with polyangiitis (GPA). The study suggests that the use of anti-TNF-alpha and abatacept shows efficacy in less than 50% of patients with refractory and/or relapsing GPA.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2022)
Review
Immunology
Angela Ceribelli, Francesca Motta, Matteo Vecellio, Natasa Isailovic, Francesco Ciccia, Carlo Selmi
Summary: Spondyloarthritis (SpA) is a group of inflammatory musculoskeletal diseases with common genetic backgrounds, and IL-17 and IL-23 have been identified as key cytokines in its pathogenesis. Treatment options for axial SpA differ significantly from peripheral arthritis, with new therapies targeting these cytokines showing promising results for both axial psoriatic arthritis and ankylosing spondylitis.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Benjamin Ehst, Zhiping Wang, Justin Leitenberger, Danielle McClanahan, Rachel De La Torre, Erika Sawka, Alex G. Ortega-Loayza, Jennifer Strunck, Teri Greiling, Eric Simpson, Yuangang Liu
Summary: IL-23 plays a crucial role in Th17 immunity and inflammatory responses, especially in diseases like psoriasis. While dendritic cells are considered the main source of IL-23 in psoriasis, there is controversy surrounding the expression of IL-23 in psoriatic keratinocytes. Research has shown that a combination of TNF alpha and IL-17A can induce IL-23 production in human keratinocytes, with enhanced effects in psoriatic keratinocytes and EGFR signaling.
Article
Allergy
Hao Li, George C. Tsokos
Summary: Inflammatory rheumatic disorders involve the immune system attacking connective tissues and internal organs. Advances in understanding the cellular and molecular mechanisms have led to targeting the IL-23/IL-17 axis therapeutically, resulting in clinical benefits. The complicated interrelationship between IL-23 and IL-17 may be uncoupled in certain disease settings.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
(2021)
Review
Chemistry, Medicinal
Darshani Patil, Ajazuddin, Sankha Bhattacharya
Summary: Autoimmune diseases are increasing in prevalence, and biologicals are playing a crucial role in their treatment by targeting specific cytokines and suppressing inflammation. Tumor Necrosis Factor-alpha (TNFa) inhibitors and Interleukin Inhibitors (IL) are common classes of biologics used for treating autoimmune diseases. In addition, nanomedicine has shown promising results in delivering drugs to targeted organs or tissues without causing unwanted immune effects. This article provides an overview of biologics in autoimmune disease treatment, their mechanisms, and the use of nanosystems in clinical trials.
CURRENT TOPICS IN MEDICINAL CHEMISTRY
(2023)
Review
Gastroenterology & Hepatology
Bram Verstockt, Azucena Salas, Bruce E. Sands, Clara Abraham, Haim Leibovitzh, Markus Neurath, Niels Vande Casteele
Summary: IL-12 and IL-23 play a crucial role in intestinal homeostasis and inflammation, and are implicated in the pathogenesis of inflammatory bowel disease. Monoclonal antibodies targeting IL-12 and/or IL-23 have been developed for the treatment of Crohn's disease and ulcerative colitis. This Review summarizes the biological characteristics of IL-12 and IL-23, discusses their role in intestinal homeostasis and inflammation, and highlights the development of drugs targeting IL-12 and/or IL-23.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2023)
Review
Immunology
Yi Ru, Xiaojie Ding, Ying Luo, Hongjin Li, Xiaoying Sun, Mi Zhou, Yaqiong Zhou, Le Kuai, Meng Xing, Liu Liu, Yue Luo, Jiankun Song, Jiale Chen, Bin Li, Xin Li
Summary: The study summarized the characteristics and mechanisms of occurrence of five immunological and non-immunological adverse events caused by different anti-IL-23 agents. The results showed that these agents tend to be well-tolerated with good safety profiles, but careful monitoring is needed for prevention of complications when administered for over approximately 40 weeks.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Dermatology
Roberto Russo, Giulia Gasparini, Emanuele Cozzani, Martina Burlando, Aurora Parodi
Summary: The lack of safety data on pregnant women makes it difficult to choose the correct biologic agent for treating psoriasis in women of childbearing potential. Studies have suggested a potential role of IL-23 in unexplained recurrent spontaneous abortions, leading to considerations about using anti-IL-23 drugs in the treatment of psoriasis in women of childbearing potential.
DERMATOLOGIC THERAPY
(2021)
Article
Gastroenterology & Hepatology
Kengo Kanayama, Jun Kato, Wataru Shiratori, Ariki Nagashima, Yuki Ohta, Takashi Taida, Keiko Saito, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Tatsuya Kaneko, Naoki Akizue, Kenichiro Okimoto, Tomoaki Matsumura, Naoya Kato
Summary: This study found that selecting subsequent treatment based on the response to initial anti-tumor necrosis factor (TNF)alpha antibody (ATA) is feasible in refractory ulcerative colitis (UC) patients. Non-ATA may be suitable as subsequent biologics for UC patients regardless of the efficacy of the first ATA.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Gonca Sarac Ozturk, Tulin Ergun, Irem Peker Eyuboglu, Mustafa Akkiprik
Summary: This study evaluated serum levels of proinflammatory cytokines and hs-CRP in HS patients, finding hs-CRP to be an indicator of treatment response and systemic inflammation. However, there is insufficient data to suggest TNF-α, IL-1β, IL-17A, and IL-23 as serum biomarkers in HS.
Article
Dermatology
Hans Christian Ring, Julia-Tatjana Maul, Yiqiu Yao, Jashin J. Wu, Jacob P. Thyssen, Simon F. Thomsen, Alexander Egeberg
Summary: In this cohort study, drug survival was comparable between adalimumab, infliximab, and ustekinumab but significantly lower for etanercept. There were no differences in drug survival among biologic-naive and nonnaive patients.
Article
Medicine, General & Internal
Dawei Huang, Yingyuan Yu, Jiajing Lu, Fei Tan, Yuling Shi
Summary: The study found that compared to tumor necrosis factor-alpha inhibitors (TNF-alpha i), interleukin-17 inhibitors (IL-17i) and interleukin-23 inhibitors (IL-23i) have a protective effect on psoriasis flare-up. Additionally, an increased proportion of people with worsened psoriasis developed long COVID-19, suggesting worsened psoriasis may be a potential risk factor for long COVID-19.
FRONTIERS IN MEDICINE
(2023)
Article
Rheumatology
Jerome Hadjadj, Alice Canzian, Omer Karadag, Anne Contis, Francois Maurier, Sebastien Sanges, Silvia Sartorelli, Laure Denis, Claire de Moreuil, Cecile-Audrey Durel, Stephane Durupt, Marie Jachiet, Diane Rouzaud, Carlo Salvarani, Roberto Padoan, Lorenzo Dagna, Fabrice Bonnet, Christian Agard, Thomas Moulinet, Marion Hermet, Raluca Sterpu, Alexandre Thibault Jacques Maria, Jeremy Keraen, Loic Guillevin, David Jayne, Benjamin Terrier
Summary: This study investigates the effectiveness and safety of biologics, particularly TCZ, in treating relapsing and/or refractory polyarteritis nodosa (PAN) patients. The results suggest that TCZ may be effective in managing PAN, but further research is needed to confirm these findings.
Review
Biochemistry & Molecular Biology
Aikaterini Tsiogka, Stamatios Gregoriou, Alexander Stratigos, Stergios Soulaidopoulos, Natalia Rompoti, Pantelis Panagakis, Marina Papoutsaki, Panagiotis Kostakis, George Kontochristopoulos, Konstantinos Tsioufis, Anna Campanati, Annamaria Offidani, Charalambos Vlachopoulos, Dimitrios Rigopoulos
Summary: Accumulating evidence suggests that psoriasis, a systemic inflammatory disorder, is associated with comorbidities such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome. Chronic systemic inflammation and T helper (Th)-1 and Th17 polarization are believed to be associated with endothelial dysfunction and accelerated atherosclerosis. This systematic review summarizes the current understanding of the pathogenesis and diagnostic evaluation of atherosclerosis in psoriasis, and reviews the impact of IL-23/Th17 axis-targeted biologic treatments on subclinical atherosclerosis in patients with psoriasis and/or psoriatic arthritis.
Review
Immunology
Shuwei Wu, Yuanyuan Xu, Lihua Yang, Linghong Guo, Xian Jiang
Summary: This comprehensive meta-analysis aimed to assess the risk of infection and malignancy in patients with psoriasis receiving interleukin (IL)-17 and IL-23 inhibitors. The results showed that the short-term and long-term risks of infection and malignancy were generally low in psoriasis patients receiving IL-17 and IL-23 inhibitors, although close monitoring is required for nasopharyngitis and Candida infection.
FRONTIERS IN IMMUNOLOGY
(2023)